3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Carcinoma, Renal Cell
2
Advanced Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Cyclophosphamide
14
Gemcitabine
6
Filgrastim
6
fludarabine
5
Methotrexate
5
Leucovorin
5
Granulocyte Colony-Stimulating Factor
5
Zoledronic Acid
4
Temozolomide
4
Mesna
4
Irinotecan
4
Ifosfamide
4
Etoposide
4
Cisplatin
4
Carboplatin
4
pembrolizumab
3
fludarabine phosphate
3
Doxorubicin
3
Biopsy
3
tanespimycin
2
poly ICLC
2
pegfilgrastim
2
lorukafusp alfa
2
liposomal doxorubicin
2
dinutuximab
2
cabozantinib
2
belinostat
2
Topotecan
2
Thalidomide
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Osteosarcoma
×
abemaciclib
×
Clear all
NCT02644460
2023-10-26
AflacST1501
Emory University
Phase 1
Completed
53 enrolled